How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO

Simply Wall St.06-17

At ASCO 2026, Exelixis reported that its pivotal phase 3 CABINET trial showed CABOMETYX significantly improved progression-free survival in patients with advanced neuroendocrine tumors, leading to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644742767?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2026-06-17 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644742767","market":"us","top_or_hot":-1,"title":"How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO","media":"Simply Wall St.","content":"<div>\n<p>At ASCO 2026, Exelixis reported that its pivotal phase 3 CABINET trial showed CABOMETYX significantly improved progression-free survival in patients with advanced neuroendocrine tumors, leading to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/how-investors-are-reacting-to-exelixis-exel-cabometyx-neuroe\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-17 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/how-investors-are-reacting-to-exelixis-exel-cabometyx-neuroe><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At ASCO 2026, Exelixis reported that its pivotal phase 3 CABINET trial showed CABOMETYX significantly improved progression-free survival in patients with advanced neuroendocrine tumors, leading to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/how-investors-are-reacting-to-exelixis-exel-cabometyx-neuroe\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/how-investors-are-reacting-to-exelixis-exel-cabometyx-neuroe","article_id":"2644742767","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/how-investors-are-reacting-to-exelixis-exel-cabometyx-neuroe","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644742767","pubTimestamp":1781706913,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"At ASCO 2026, Exelixis reported that its pivotal phase 3 CABINET trial showed CABOMETYX significantly improved progression-free survival in patients with advanced neuroendocrine tumors, leading to early trial termination for superior efficacy.\nAn important nuance is that CABOMETYX showed benefit across both functional and non-functional neuroendocrine tumor subgroups, potentially broadening its clinical and commercial relevance within this diverse cancer population.\nWe’ll now consider how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","ISBC":"投资者银行","EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓","BK4139":"生物科技"},"translate_title":"投资者对Exelixis(EXEL)CABOMETYX神经内分泌肿瘤3期在ASCO获胜有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"EXEL":1.5},"content_text":"At ASCO 2026, Exelixis reported that its pivotal phase 3 CABINET trial showed CABOMETYX significantly improved progression-free survival in patients with advanced neuroendocrine tumors, leading to early trial termination for superior efficacy. An important nuance is that CABOMETYX showed benefit across both functional and non-functional neuroendocrine tumor subgroups, potentially broadening its clinical and commercial relevance within this diverse cancer population. We’ll now consider how CABOMETYX’s phase 3 success in both functional and non-functional neuroendocrine tumors may reshape Exelixis’ investment narrative. Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.AdvertisementExelixis Investment Narrative RecapTo own Exelixis, you need to believe cabozantinib can keep anchoring the business while new indications and pipeline assets gradually reduce single-drug dependence. The CABINET success in neuroendocrine tumors reinforces CABOMETYX’s central role and looks supportive for near term revenue momentum, but it does not remove the key risk around future patent expiry and pricing pressure, which remain the most important issues to watch in the coming years. Among recent updates, the February 2026 FDA acceptance of Exelixis’ NDA for zanzalintinib plus atezolizumab in metastatic colorectal cancer is most relevant here. Together with CABINET, it highlights how Exelixis is trying to broaden its oncology footprint beyond cabozantinib, setting up zanzalintinib as a potential second meaningful revenue pillar and an important counterweight to future generic risk on CABOMETYX. Yet, while CABINET is encouraging, investors should still pay close attention to how exposed Exelixis remains to future pricing pressure and patent erosion on CABOMETYX... Read the full narrative on Exelixis (it's free!)Exelixis’ narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029. This requires 12.0% yearly revenue growth and an earnings increase of about $400 million from $833.4 million today.Uncover how Exelixis' forecasts yield a $49.65 fair value, a 5% downside to its current price.Exploring Other PerspectivesEXEL 1-Year Stock Price Chart Some analysts were far more cautious before CABINET, assuming revenue of about US$2.4 billion and earnings near US$590 million by 2029, reminding you that views on Exelixis’ dependence on CABOMETYX and future margins can differ sharply and may shift again as the neuroendocrine tumor data are fully absorbed.Explore 8 other fair value estimates on Exelixis - why the stock might be worth 7% less than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.Curious About Other Options?Our daily scans reveal stocks with breakout potential. Don't miss this chance:The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644742767","isCrawlerRequest":true}